The essential thrombocythemia market is expected to grow steadily due to increasing disease prevalence, advancements in targeted therapies, and rising awareness. The development of JAK inhibitors and ...
The Shorespan-007 trial will investigate the new drug among patients with essential thrombocythemia who have not previously received cytoreductive therapy. A second phase 3 clinical trial has been ...
Educated Patient® MPN Summit Defining Essential Thrombocythemia Risk Presentation: November 19, 2022
Understanding the different types of risks faced by people with essential thrombocythemia, a type of cancer associated with uncontrolled growth of blood platelets, is crucial to helping patients live ...
Essential thrombocythemia (ET) is a rare condition affecting the bone marrow, resulting in an overproduction of platelets. It usually affects those over the age of 50, progresses slowly, and can be ...
Beyond PEGASYS, the essential thrombocythemia treatment landscape is evolving with several promising assets in the pipeline. These include BESREMi (ropeginterferon alfa-2b), Bomedemstat ...
Dear Dr. Gott: I have been diagnosed with essential thrombocytosis. I am being treated with hydroxyurea. I also experience leg cramps, neuropathy in my feet and a dropped left foot. I previously had ...
The predictive value of the MASCC score in patients with febrile neutropenia. Effects of various non-demographic variables on mortality and length of stay in stroke patients with history of ET.
Dear Dr. Roach: I am a 60-year-old woman, recently diagnosed with essential thrombocytosis, which apparently is rare and a form of bone marrow cancer. It was found during a routine blood test, and I ...
Dear Dr. Gott: I have been diagnosed with essential thrombocytosis. I am being treated with hydroxyurea. I also experience leg cramps, neuropathy in my feet and a dropped left foot. I previously had ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results